The ecosystem of Biotech ventures peaked in 2021. Mubadala is a sovereign wealth fund, investing on behalf of the United Arab Emirates and the government of Abu Dhabi. Following is a list of the top 15 venture capital firms in 2023. All Rights Reserved. Many investors contributed their efforts in early-stage Biotech to find the next Moderna. htmlbody height HTML body div The management team, combined with its advisory board, includes seasoned entrepreneurial, medical device sector, venture capital, regulatory, and scientific expertise. Insights about top trending companies, startups, investments and M&A activities, notable investors of these companies, their management team, and recent City (cities) where offices are located: Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, Chicago; Cambridge, MA; as well as affiliate operations in Beijing; Shanghai; Bangalore; Mumbai. Morgenthaler VenturesLife Sciences Team, City (cities) where offices are located: Palo Alto, CA; Boston; Boulder, CO, Fund size and status: More than $2.5 billion under management, Current fund: $400 million Fund IX, closed 2008 and used in part for investment in life-sciences companies. But two of those investment firms have emerged as major leaders, not only in the number of biotech funding rounds led, but also in overall dollars invested into the industry. Venture Crunchbase Pro queries listed for this article. Content continues It is typical for venture capital firms to identify and back companies in high technology industries and so venture capital is most active in the fast-growing technology and life sciences or biotechnology fields. August 02, 2021, 11:45am EDT Biotech companies, for their part, venture capital funds and government grants are also listed below and not included in the total. See: http://finance.yahoo.com/news/lightstone-ventures-closes-first-fund-123257593.html Biotech Venture Capital Firms: Top Venture Capital Firms. Along with conventional medicinal biopharma, the firms portfolio also includes a variety of technologies and online health start-ups. The firm seeks to make minority investments in seed, early-stage, and later-stage companies. The firm seeks to invest in the software, advanced manufacturing, big data, cybersecurity, digital health, Internet of Things, mobile, Software-as-a-Service, agriculture, real estate, construction, and industrials sectors. The biotech market has set a record for the number of initial public offerings in 2021. Cormorant Capital, a Boston-based investing group with $3 billion in assets under management, was founded in 2013 by Bihua Chen. See: http://www.sec.gov/Archives/edgar/data/1611731/000161173114000001/xslFormDX01/primary_doc.xml. Venture capital is the lifeblood of breakthrough medical technologies. Being bicoastal, the company primarily invests in the US eastern seaboard but has an international presence. Venture capital in U.S. and Europe biotechnology industry 2015-2021 U.S. bioscience venture capital investments by segment 2018-2021 biotechnology funding by National Institutes for Health 2013-2023 RA Capital led the companys $336 million Series C ahead of the companys August IPO, though the firm hadnt participated in the companys earlier funding rounds. But it had holdings in nine biotech companies that went public this year, including Vor Biopharma, Omega Therapeutics, and Adagio Therapeutics. Managing Directors Thomas Ball and Michael Smerklo. Over the last 31 years, the firm has managed a highly diversified $5 billion fund that comprises some of the top names in technology and life sciences. Largest investment: 37.5 million shares of Instil Bio worth $751 million at the time of its IPO, Total holding value of 2021 IPOs: $750.6 million. Webby Maureen Martino and Calisha Myers We here at FierceBiotech regularly chronicle the largest venture capital deals in biotech. Early Stage VC, Later Stage VC, Seed Round. Essex Woodlands Health Ventures, City (cities) where offices are located: Palo Alto, CA; Houston; New York; London; Shanghai, Fund size and status: More than $2.5 billion under management across eight funds (4), Current fund: $900 million Fund VIII, closed 2009 (4), Current biopharma portfolio companies: Acura Pharmaceuticals, Biotoscana, Bioventus, Catalyst Biosciences, Chroma Therapeutics, Corium, Curis, Echo Therapeutics, Elusys Therapeutics, Horizon Pharma, IntegenX, LightSciences Oncology, Medicinova, Molecular Partners, Open Monoclonal Technology, Oraya Therapeutics, Revance Therapeutics, Symphogen, Ziopharm Oncology, City (cities) where offices are located: Cambridge, MA; New York; Palo Alto, CA, Fund size and status: $2.6 billion under management across seven funds, Current funds: $450 million Venrock VII, closed July 2014 and intended to invest in technology and healthcare companies; $350 million Venrock VI, closed 2010 (5), Current biopharma portfolio companies: Acceleron Pharma, Achaogen, Anacor Pharmaceuticals, Ariosa Diagnostics, Avalanche Biotech, AVEO Pharmaceuticals, Celladon, Cerulean, Constellation Pharmaceuticals, CymaBay Therapeutics, Fate Therapeutics, Hua Medicine, Infinity Pharmaceuticals, Intarcia Therapeutics, Ironwood Pharma, Juno Therapeutics, QuatRx Pharmaceuticals, Receptos, Vitae Pharmaceuticals, City (cities) where offices are located: Boston (6); South San Francisco, CA; Gainesville, FL; Munich, Fund size and status: More than $2.6 billion committed capital under management across five funds, Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010 (7), Current biopharma portfolio companies: 23andMe, Amphivena Therapeutics, Anthera Pharmaceuticals, Aratana Therapeutics, Astute Medical, Celladon, Cerecor, Chiasma, Conatus Pharmaceuticals, Epizyme, Iconic Therapeutics, Mitokyne, Proteon Therapeutics, Radius Health, Rhythm Pharmaceuticals, SAI, Selexys Pharmaceuticals, Sideris Pharmaceuticals, Solasia Pharma, Syndax Pharmaceuticals, Theraclone Sciences, True North Therapeutics, Vascular Pharmaceuticals, Verastem, City (cities) where offices are located: Princeton, NJ, and San Diego, Fund size and status: More than $2.7 billion under management across eight funds, Current fund: $500 million Domain Partners VIII, closed 2009, Current biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Aldeyra Therapeutics, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, Atara Biotherapeutics, aTyr Pharma, BioNano Genomics, Cantex Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Dicerna Pharmaceuticals, Domain Elite Holdings, Domain Russia Investments, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Marinus Pharmaceuticals, Meritage Pharma, NovaDigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ProteinSimple, Regardo Biosciences, Sera Prognostics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix, Fund size and status: $2.8 billion under management across 10 funds, Current fund: $650 million InterWest Partners X, closed 2008, Current biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Arcion Therapeutics, Carbylan Therapeutics, Cebix, Centrexion, Cidara Therapeutics, Drais Pharmaceuticals, Eiger BioPharmaceuticals, Lycera, MacroGenics, Ocera Therapeutics, On Demand Therapeutics, Paratek Pharmaceuticals, PMV Pharma, QuatRx Pharmaceuticals, RadioRx, Tesaro, Trius Therapeutics, USDS, Xenon Pharmaceuticals, City (cities) where offices are located: Cambridge, MA. Six top firms held more than $1 billion in equity: Arch Venture Partners, Novo Holdings, Flagship Pioneering, RA Capital Management, Perceptive Advisors, and SoftBank. After all, you cannot rush your way into building long-term relationships! Among RA Capital and OrbiMeds big bets this year was. The New York-based OrbiMed Healthcare Fund Management has made various investments in the life sciences sector, including MedTech and Biopharma. The firm primarily works in the Biopharma industry and has a remarkable in-house scientific breakthrough research facility called Versants Discovery Engines. However, as the COVID Biotechnology boom ends, it is becoming more challenging for entrepreneurs to get venture money. With a strong M&A environment for exits, venture capitalists continue to fuel biotech industry growth. CFO Alyssa Dadoly, Partners Kip Mcclanahan, Mike Dodd, Morgan Flager, and Roger Chen. Early Stage VC, Later Stage VC, Merger/Acquisition, Founded in 2018, Ecliptic Capital is a venture capital firm based in Austin, Texas. One of the key She has grown Cormorant into one of biotech top investors; the company was involved in 11 such IPOs in 2021. Asia Pacific ; On May 1 of this year, Lightstone announced it closed its first fund at $172 million. CEO: Andrew Sheiner. Vivo is a healthcare-focused VC firm with $5.8 billion in assets under management. Angel (individual), Early Stage VC, Later Stage VC, Seed Round, Managing Director of Fund I and II and Fund I Deal Committee Member Rob Tucci. Largest investment: 16.2 million shares of Theseus Pharmaceuticals worth $259 million at the time of its IPO, Total holding value of 2021 IPOs: $988.4 million. WebThe 45 most important VCs in Texas, according to other VCs. Polaris Partners became the latest VC firm in the money on November 24, when it announced it had closed on its $450 million seventh fund, to be focused on healthcare and technology investments. It closed its second Xontogeny-focused fund in May, giving it another $515 million to invest in a dozen or more companies. The firm prefers to invest in the direct-to-consumer, food and beverage, health and beauty, sports and fitness, apparel and accessories, accessible luxury, wellness, LOHAS, aging population, sustainable products, demand for personalization, humanization of pets, omnichannel, fem tech, and end of life sectors. Our Standards: The Thomson Reuters Trust Principles. Boston-based RA Capital Management and New York-based OrbiMed ranked first and second, respectively, on the two lists compiled using Crunchbase data. Over the next 12 months, the analysts expect to see more signs of overcrowding in the SPAC market, including a year on year decline in SPAC IPO volume. See: http://fortune.com/2014/10/02/exclusive-atlas-venture-is-splitting-up/ Medtech. ENT Biotech Solutions is a Michigan-based venture company that develops a novel medical device created by a practicing Otolaryngologist to remove tonsils/adenoids and soft tissue. The largest deal of 2021 was the transaction of Treeline Biosciences (USD 735m), while the most active investor was Alexandria Venture Investments with 51 investments in 2021. WebThe 45 most important VCs in Texas, according to other VCs. It is owned entirely by the Novo Nordisk Foundation, the holdings limited of the Novo Group. Since 1996, Alta Partners, a renowned life science venture capital firm, has invested in over 130 businesses. This venture capital firm is one of the top investors in the life sciences, with a track record of more than 260 firms and a total capital of $2.8 billion+. The firm and its SPAC partner, General Catalyst, have until March 2023 to find a company to acquire or return the money to investors. The firm seeks to invest in early-stage breakthrough technologies. Just last month, Canaan Partners closed on its $675 million tenth fund. The firms themselves are the sources of much of the information, though in some instances, amounts of capital under management were calculated by adding the value of newly closed funds with previously disclosed amounts. The Indian startup/ VC ecosystem will truly come of age Essex Woodlands was established by the Essex Venture Fund. Fund size and status: More than $14 billion in committed capital across 14 funds, Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed 2012, Current biopharma portfolio companies: 3-V Biosciences, Acadia Pharmaceuticals, Adaptimmune, Alimera Sciences, Amicus Therapeutics, Ardelyx, Blend Therapeutics, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Cerecor, Cleave Biosciences, Clovis Oncology, Cydan, Dermira, Edimer Pharmaceuticals, Envisia Therapeutics, Epizyme, Galera Therapeutics, Glycomimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Intrinsic Therapeutics, Liquidia Technologies, Loxo Oncology, Lumos Pharma, Mersana Therapeutics, Mirna Therapeutics, Nexchem, NexImmune, Novast Holdings, Predictive Biosciences, Prosensa, Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Roka Bioscience, Satori Pharmaceuticals, Sunesis Pharmaceuticals, Supernus Pharmaceuticals, Targacept, Tesaro, Transcept Pharmaceuticals, Tracon Pharmaceuticals, Trevena, Zyngenia, 1 The firm was ending investments in life sciences, and raising a fund in the $200 million range, according to an April 4 news report in Venture Capital Dispatch, a blog of The Wall Street Journal, in which the firm declined comment. CEO: John Doerr (chairman), Brook Byers (founder). Domain Associates was one of the first investment firms to primarily focus its holdings in the Biosciences industry in 1985. Technology and healthcare are two areas in which California-based New Enterprise Associates, Inc invests. Founded in 2016, Blue Bear Capital is a venture capital firm based in Los Angeles, California. Here is a breakdown of some of those leaders, based on Crunchbase data. Nearly $20 billion in funding flowed into biotech companies developing cell-, gene- and tissue-based therapies last year, widely eclipsing the total invested in 2019 and ending up 50% higher than the previous record of $13.5 billion set in 2018. The firm seeks to invest in the software as a services (SaaS), cloud, data science, and artificial intelligence sectors. Largest investment: 13.2 million shares of Lyell Immunopharma worth $225.8 million at the time of its IPO, Total holding value of 2021 IPOs: $400.2 million. Investment into biotech and health care boomed during the pandemic as thousands of venture capital firms turned their attention to breakthrough artificial intelligence, cancer-detection technology, mental health treatments, digital doctor visits, diagnostics and more. Early Stage VC, Later Stage VC, PE Growth/Expansion, Seed Round. In addition to holding shares in four biotechs that went public this year, Foresite was involved in two SPAC deals for the biomarker and diagnostics firm SomaLogic and the protein-sequencing company Quantum-Si that went through this year, giving it more capital to deploy in 2022. See here for a complete list of exchanges and delays. This years list shows the upward progression of VC firms; the lowest-ranked of this years firms had $1.25 billion under management, compared with more than $1.1 billion for the Top 30 Venture Capital Firms of 2013. The trend of increased biotech venture capital continues in 2021 with the newly announced fund NFX Bio. Novo Holdings; ARCH; Flagship Pioneering; Rachel Mendelson/Insider, Guido Kirchner/picture alliance via Getty Images, Photo by Pat Greenhouse/The Boston Globe via Getty Images, Alessandro Di Ciommo/NurPhoto via Getty Images, transitioned to investing in private companies, $515 million to invest in a dozen or more companies, previously told Insider about the four-step creation process. MicroVentures is an online equity crowdfunding platform enabling angel investors to connect with startups to raise capital. Does the firm have any background in technology similar to yours? 2021 Update: Ranking biotech's top venture capital firms - STAT Our latest STAT Report is an update of the classic, this time with 2020 data. Founded in 2005, Mercury Fund is a venture capital firm based in Houston, Texas. Alta Partners. The companys life science and healthcare investment portfolio spans the Biopharmaceutical, Biotechnology, medical equipment, services, and information and technology industries. WebWith a total of USD 9.2bn, the oncology sector received the highest funding volume, followed by central nervous system (USD 6.0bn) and infectious diseases (USD 2.2bn). So far, the companies have raised a total of $12.2 billion in capital. Flagship Pioneering offers a distinctive business strategy that conceives, develops, finances, and expands first-in-category ventures to revolutionize sustainability and human health. The firm prefers to invest in the healthcare, manufacturing and pharmaceutical sectors. However, the situation has tremendously changed since the market crash began in November 2021. It has a variety of technologies spanning Biopharma, engineering, food, and other areas. The rise in transaction volume may be attributed to the increase in transaction sizes as the top firms receive extensive working capital. Novo Holdings is the massive corporate investment arm of the Novo Nordisk Foundation, which is a majority shareholder in the Danish drugmaking giant Novo Nordisk. This report is informational only. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! Here's Fierce Biotech's look at the InterWest spends an aggregate of $7 to $15 million on each portfolio business during their engagement, covering the whole spectrum of venture investment phases. Partners & Co-Founders Brad Bentz, Danielle Weiss Allen and Chris Shonk. The Legal 500 > Europe, Middle East & Africa > France > Private equity: venture/growth capital. There is mixed news heading into 2021 on the COVID-19 pandemic front, with rising infection levels and a handful of vaccines showing promise. Texas Halo Fund is an investment firm based in Houston, Texas. Amidst rising interest rates and the looming threat of recession, the once-hot IPO market has come to a grinding halt. WebInsider analyzed more than 90 IPOs to find the top venture-capital firms that led biotech in 2021. Its biggest success, Moderna, has vaulted Flagship into biotech's top ranks with its COVID-19 vaccine. Since then, the company has raised seven more funds, totaling over $2.5 billion, making it one of the worlds largest and most renowned Biosciences venture capital companies. Versant, based in San Francisco, has $4.1 billion in assets under management and makes a handful of investments in new companies each year, typically investing $20 million to $30 million, a spokesperson said. as thousands of venture capital firms turned their attention to breakthrough artificial intelligence, cancer-detection technology, mental health treatments, digital doctor visits, diagnostics and more. Insider analyzed more than 90 IPOs to find the top venture-capital firms that led biotech in 2021. Acute Care EHR A Buyers Guide, Analysis of the Concept: Importance of Continuing Education for Nurses, CCPA Securing Consumer Data with Stringent Compliance Framework, Content Marketing for Healthcare [Freeguide], Digitalization is Transforming the Email Behavior of Healthcare Providers [Whitepaper], Email Engagement Metrics of Different Devices, Email Statistics to Inspire Holiday Marketing in 2019, GDPR Strengthening the Security of Sensitive Patient Data, Global Healthcare Education Market Analysis and Forecast to 2025, Guide on Emailing Physicians A Tool Kit to Better Target Physicians [Freeguide], Guide to Healthcare Marketing An Insight into the Marketing World, Guide to Use Healthcare Data Effectively for your Business, Guidelines For Developing Successful Email Campaigns For Pharmacists [Freeguide], Healthcare Email Marketing Survey for Better Insights, Accountable Care Organization (ACO) Email Database, Allied Healthcare Professional Email List, Cognitive & Behavioral Specialist Email List, Director of Biomedical Engineering Email List, Director of Central Sterile Services Email List, Healthcare Marketing Decision Makers Email List, Patient Financial Services Director Email List, Quality Patient Safety Risk Governance Director Email List, Healthcare in 2021 Trends, Growth, and Technology, Healthcare Marketing Survey amidst COVID-19, How Digital Channels Influences Hospital Administrators Purchase Decision, How to Generate Reliable Healthcare Leads [Freeguide], How to Retain Patients and Build Loyalty in Digital Age [Freeguide], Insight on Communication and Purchasing Preferences of Healthcare Organizations [Whitepaper], Integrated Delivery Networks and their Growing Influence on Regional Healthcare in the US, Leverage Emerging Technologies to Enhance Healthcare Marketing [Whitepaper], Leveraging Data for Health Care Innovation, Medical and Healthcare Facilities Email List, Licensed Nursing Home Administrator Email Addresses, Medical Device Industry Watch Trends To Watch, Registered Nurses Email List and Mailing List Marketing Database, Anatomical Clinical Pathologist Email List, Statistical Insight into Top 50 U.S Hospitals, Cardiothoracic Vascular Surgery Specialist Email List, Plastic and Reconstructive Surgeons Email List, Survey on Navigating Healthcare Marketing in 2022, Taking Care of the Elderly A Detailed Report on Nursing Homes in the US, The Essential Pillars of Digital Transformation, The Global Healthcare Outlook of the Year 2020, The Statistical Dynamics of the U.S. Elder Care Services Market, The US Pharmacy Market Overview An Account of the Statistics, Clinical Specialists-Therapists Email List, Marketing Using Physical Therapist Mailing List, Massage Therapists Email And Mailing List, Occupational Therapy Assistants Email List, Understanding the Numbers of Home Healthcare Agencies, Vaccine Market In USA and Forecast Overview, The Future of Assistive Technology in Healthcare Industry, How To Advertise To Nurses In Order To Increase Your Business Sales, Best Healthcare Data Analytics Tools in the Market, The Top 10 Clinical Research Companies in the USA. To date, over 70 of the companys life science products have received FDA approval. The firm seeks to invest globally into start-up and high growth companies with technologies of strategic importance to Saudi Aramco and to accelerate their development and deployment in the firm operations. Despite the venture boom, fundraising by new niche VCs in America has fallen from a peak of $14bn in 2018 to an expected $5.5bn in 2021. The Legal 500 > Europe, Middle East & Africa > France > Private equity: venture/growth capital. Arch Venture Partners, based in Chicago, is one of the biggest names in biotech investing its cofounder Robert Nelsen told Insider in February that he estimated that 20% of the world's biotech venture-capital dollars flowed through the firm's portfolio companies. As a spin-off of the Sprout Group, NLVP has been participating in Biopharma since 2005. Webventure funding. Which Current Shows Do You Actually Watch New Episodes Of Week By Week? Fierce Healthcare. SoftBank, based in Tokyo, has a reputation for placing large bets on bold ideas. In a handful of instances, figures and facts came from biographies of the firms principals available on the websites of investee companies and publicly available investor presentations posted online. Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Just eight months into this new SPAC phenomenon, weve already seen signs of oversaturation in the market, with a recent uptick in the number of downsized SPAC IPOs, PitchBook analysts said. Octopus Ventures is a London and New York based venture capital firm, focused on backing unusually talented entrepreneurs. The company focuses on first-in-class goods and cutting-edge, disruptive technologies. The analysis included 93 biotechs listed on the IPO trackers managed by BioPharma Dive and Endpoints News as of December 6. The firm seeks to invest in the business products and services sectors. Founded in 1989, OrbiMed, an investing powerhouse based in New York, has shaped biotech for decades with its investments. These VC firms led the most funding rounds for biotech startups this year between Jan. 1 and Dec. 1, according to Crunchbase data. Largest investment: 11.9 million shares of Century Therapeutics worth $238.5 million at the time of its IPO, Total holding value of 2021 IPOs: $416.6 million. Here is a list of the most active most active bio-tech, pharma and life science investors. Largest investment: 17.9 million shares of Evotec worth $936 million at the time of its IPO, Total holding value of 2021 IPOs: $1.6 billion. The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Mercks venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. The list is ordered starting with the companies who invested the most in biotechnology. The company is steadily growing its life science footprint, emphasizing infrastructure, financial instruments, and real estate. Largest investment: 12.1 million shares of Instil Bio worth $244 million at the time of its IPO, Total holding value of 2021 IPOs: $425.7 million. Boston Cambridge Massachusetts Consistently, the top state for biotechnology industries in Massachusetts, particularly in the Greater Boston area. Boost Heroes The firm seeks to invest in companies operating in the information technology and tech-enabled services. Founded in 1999, Chevron Technology Ventures is the corporate venture capital arm of Chevron and is based in Houston, Texas. WebAsk any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. Founded in 2006, Silverton Partners is a venture capital firm and is based in Austin, Texas. Our research shows that VC companies invested in 2,200 biotech start-ups worldwide in 2016; by 2021, that number had grown to 3,100. Kleiner Perkins Caufield & Byers (KPCB), City (cities) where offices are located: Menlo Park, CA; San Francisco; Beijing; Shanghai, Fund size and status: More than $7 billion in assets under management across 19 funds (13), Current fund: $525 million KPCB XV, closed 2012 (13), Current biopharma portfolio companies:(14) ApniCure, Armo BioSciences, Atara Bio, Auxogyn, Crescendo Bioscience, Elcelyx, Epizyme, FivePrime Therapeutics, Focal, Foundation Medicine, Oculeve, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Practice Fusion, Rapid Micro Biosystems, Tesaro, True North Therapeutics. Over the years, Boston has steadily built a tech hub that rivals other cities in the country. biotech in 2021 VIEW SLIDESHOW 10 photos By Rowan Walrath Life Sciences Reporter, Boston Business Journal Dec 29,